Provided herein, among other things, is an engineered non-plant cell that produces a tropane alkaloid product, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product. A method for producing a tropane alkaloid, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product that makes use of the cell is also described.

The invention relates to a genetically modified fungal microorganism for the production of frambinone, the microorganism having the following characteristics: —the capacity to produce frambinone from tyrosine; and —a limited capacity or no capacity to break tyrosine down into tyrosol, p-hydroxyphenylacetaldehyde and/or p-hydroxyphenylacetate; and to the use of same for producing frambinone.

The present invention relates to a genetically modified host cell producing a bibenzylic acid or a derivative thereof expressing a) one or more genes encoding a polyketide synthase (PKS); b) one or more genes encoding a polyketide cyclase (PKC); and c) one or more genes encoding a double bond reductase (DBR); and one or more genes encoding polypeptides selected from d) a tyrosine ammonia lyase polypeptide (TAL); e) a phenylalanine ammonia lyase polypeptide (PAL); f) a cinnamate 4-hydroxylase polypeptide (C4H); g) a cytochrome p450 reductase polypeptide (CPR); h) a 4-coumarate-CoA ligase polypeptide (4CL); and/or i) a non-catalytic chalcone isomerase type III or IV polypeptide (CHIL); wherein the at least one gene is heterologous to the host cell.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.

Provided is an immobilized enzyme, a preparation method and use thereof. The immobilized enzyme includes an enzyme and an amino resin carrier for immobilizing the enzyme, and the enzyme is selected from any one of the following enzymes: transaminase, ketoreductase, monooxygenase, ammonia-lyase, ene reductase, imine reductase, amino acid dehydrogenase, and nitrilase. The amino resin carrier is an amino resin carrier modified by a cross-linking agent, and the cross-linking agent is a cross-linking agent treated by a polymer. By means of modifying the amino resin carrier with the cross-linking agent treated by the polymer, the enzyme immobilized on the amino resin carrier may easily form a network cross-linking, such that the immobilization effect of the enzyme is more stable, thereby the recycling efficiency of the enzyme is improved.

The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity and enhanced acid stability, while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.

The present invention provides engineered phenylalanine ammonia lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia lyase (PAL) polypeptides. In some embodiments, the engineered PAL polypeptides are optimized to provide enhanced catalytic activity, as well as reduced sensitivity to proteolysis and increased tolerance to storage at elevated temperatures. In some embodiments, the engineered PAL polypeptides contain fewer phenylalanine residues than wild-type PAL polypeptides. The present invention also provides methods for the use of the compositions comprising the engineered PAL polypeptides for therapeutic and industrial purposes.

Genetically engineered microorganisms, e.g., genetically engineered bacteria, compositions and formulations thereof, as well as methods for characterizing, dosing, and determining the activity of the bacteria, compositions, and formulations, e.g., using a live cell counting method are disclosed.

The present invention provides engineered tyrosine ammonia-lyase (TAL) polypeptides and compositions thereof. In some embodiments, the engineered TAL polypeptides have been optimized to provide enhanced catalytic activity and enhanced acid stability, while reducing sensitivity to proteolysis and increasing tolerance to acidic pH levels. The invention also provides methods for utilization of the compositions comprising the engineered TAL polypeptides for therapeutic and industrial purposes.